Skip to main content
Figure 4 | Journal of Translational Medicine

Figure 4

From: Dual effects of a targeted small-molecule inhibitor (cabozantinib) on immune-mediated killing of tumor cells and immune tumor microenvironment permissiveness when combined with a cancer vaccine

Figure 4

Cabozantinib reduces tumor vascularity and improves T cell infiltration when combined with a cancer vaccine. (A) Schema of combination therapy study (n =2/group). (B) Representative histological staining for indicated markers (top) on tumor sections from mice given indicated treatments (left). Inset panels: isotype staining. (C-F) Quantification of (C) blood vessels/tumor section; (D) number of CD3+ T-cells/tumor section; (E) number of CD4+ T-cells /tumor section; and (F) number of CD8+ T-cells /tumor section. Inset panels: number of indicated cells/mm2 of tumor. Marker staining was identified and enumerated using Aperio ImageScope image analysis software. Error bars indicate mean ± SEM. Statistical analyses were done by Student's t test. * = P <0.05 relative to control.

Back to article page